drugset / Trial / NCT02901145
Nivolumab in Relapsed Pediatric Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
patients with progressive/relapsed solid tumors who failed first line therapy , will be treated biweekly with the anti PD1- Nivolumab. at least one month after treatment initiation low dose cyclophosphamide will be started . patients on trial will submit tissue and blood tests for whole exome an immune genomic signature. patients will also undergo repeated immunophenotype as part of follow up.
Timeline
- Start
- 2016-11
- Primary completion
- 2019-11
- Completion
- 2020-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
Indications
No indication recorded.